SCD5-driven reprogramming of FA metabolism has been shown to block epithelial–mesenchymal transition, thereby reducing the probability of metastatic events and tumor malignancy in breast cancer [21] and melanoma [22,23]. This evidence concerns the gene SCD5 and breast cancer.